The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Database Searching
2.2. Inclusion and Exclusion Criteria
2.2.1. Inclusion Criteria
2.2.2. Exclusion Criteria
2.3. Study Selection and Data Extraction
2.4. Primary Outcomes
2.5. Secondary Outcomes
2.6. Risk of Bias Assessment
2.7. Statistical Analysis
3. Results
3.1. Study Selection
3.2. Characteristics of the Studies
3.3. Risk of Bias and Quality Assessment
3.4. Primary Outcomes
3.4.1. Psoriasis Area Severity Index (PASI)
3.4.2. Dermatology Life Quality Index (DLQI)
3.5. Secondary Outcomes
3.5.1. PASI 75% Reduction
3.5.2. Lipid Profile
4. Discussion
4.1. Main Findings
4.2. Implications
4.3. Limitations
4.4. Recommendations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Parisi, R.; Symmons, D.P.; Griffiths, C.E.; Ashcroft, D.M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013, 133, 377–385. [Google Scholar] [CrossRef]
- Parisi, R.; Iskandar, I.Y.K.; Kontopantelis, E.; Augustin, M.; Griffiths, C.E.M.; Ashcroft, D.M. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ 2020, 369, m1590. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Krueger, J.G. The immunopathogenesis of psoriasis. Dermatol. Clin. 2015, 33, 13–23. [Google Scholar] [CrossRef]
- Krueger, G.; Ellis, C.N. Psoriasis–recent advances in understanding its pathogenesis and treatment. J. Am. Acad. Dermatol. 2005, 53 (Suppl. S1), S94–S100. [Google Scholar] [CrossRef]
- Rendon, A.; Schäkel, K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 2019, 20, 1475. [Google Scholar] [CrossRef]
- Burfield, L.; Burden, A. Psoriasis. J. R. Coll. Physicians Edinb. 2013, 43, 334–338; quiz 339. [Google Scholar] [CrossRef]
- Chan, C.S.; Van Voorhees, A.S.; Lebwohl, M.G.; Korman, N.J.; Young, M.; Bebo, B.F.; Kalb, R.E.; Hsu, S. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 2009, 60, 962–971. [Google Scholar] [CrossRef]
- Raharja, A.; Mahil, S.K.; Barker, J.N. Psoriasis: A brief overview. Clin. Med. 2021, 21, 170–173. [Google Scholar] [CrossRef]
- Nast, A.; Boehncke, W.H.; Mrowietz, U.; Ockenfels, H.M.; Philipp, S.; Reich, K.; Rosenbach, T.; Sammain, A.; Schlaeger, M.; Sebastian, M.; et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch. Dermatol. Res. 2012, 304, 87–113. [Google Scholar] [CrossRef]
- Pariser, D.M.; Bagel, J.; Gelfand, J.M.; Korman, N.J.; Ritchlin, C.T.; Strober, B.E.; Van Voorhees, A.S.; Young, M.; Rittenberg, S.; Lebwohl, M.G.; et al. National Psoriasis Foundation clinical consensus on disease severity. Arch. Dermatol. 2007, 143, 239–242. [Google Scholar] [CrossRef]
- Mason, A.R.; Mason, J.; Cork, M.; Dooley, G.; Hancock, H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst. Rev. 2013, 2013, CD005028. [Google Scholar] [CrossRef]
- Maul, J.-T.; Anzengruber, F.; Conrad, C.; Cozzio, A.; Häusermann, P.; Jalili, A.; Kolios, A.G.; Laffitte, E.; Lapointe, A.-K.; Mainetti, C.; et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology 2021, 237, 166–178. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Puig, L.; Joshi, A.; Skup, M.; Williams, D.; Li, J.; Betts, K.A.; Augustin, M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020, 156, 258–269. [Google Scholar] [CrossRef]
- Mosiewicz, J.; Pietrzak, A.; Chodorowska, G.; Trojnar, M.; Szepietowski, J.; Reich, K.; Rizzo, M. Rational for statin use in psoriatic patients. Arch. Dermatol. Res. 2013, 305, 467–472. [Google Scholar] [CrossRef]
- Chou, R.; Cantor, A.; Dana, T.; Wagner, J.; Ahmed, A.Y.; Fu, R.; Ferencik, M. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2022, 328, 754. [Google Scholar] [CrossRef]
- Sahebkar, A.; Rathouska, J.; Derosa, G.; Maffioli, P.; Nachtigal, P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmun. Rev. 2016, 15, 344–353. [Google Scholar] [CrossRef]
- Dehnavi, S.; Sohrabi, N.; Sadeghi, M.; Lansberg, P.; Banach, M.; Al-Rasadi, K.; Johnston, T.P.; Sahebkar, A. Statins and autoimmunity: State-of-the-art. Pharmacol. Ther. 2020, 214, 107614. [Google Scholar] [CrossRef]
- Zeiser, R. Immune modulatory effects of statins. Immunology 2018, 154, 69–75. [Google Scholar] [CrossRef]
- Greenwood, J.; Steinman, L.; Zamvil, S.S. Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat. Rev. Immunol. 2006, 6, 358–370. [Google Scholar] [CrossRef]
- Costenbader, K.H.; Coblyn, J.S. Statin Therapy in Rheumatoid Arthritis. South. Med. J. 2005, 98, 534–540. [Google Scholar] [CrossRef]
- Pietrzak, A.; Michalak-Stoma, A.; Chodorowska, G.; Szepietowski, J.C. Lipid Disturbances in Psoriasis: An Update. Mediat. Inflamm. 2010, 2010, 535612. [Google Scholar] [CrossRef]
- Liu, L.; Wang, J.; Li, H.-J.; Zhang, S.; Jin, M.-Z.; Chen, S.-T.; Sun, X.-Y.; Zhou, Y.-Q.; Lu, Y.; Yang, D.; et al. Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms. Front. Immunol. 2021, 12, 759276. [Google Scholar] [CrossRef]
- Matwiejuk, M.; Mysliwiec, H.; Jakubowicz-Zalewska, O.; Chabowski, A.; Flisiak, I. Effects of hypolipidemic drugs on psoriasis. Metabolites 2023, 13, 493. [Google Scholar] [CrossRef]
- Ramessur, R.; Gill, D. The effect of statins on severity of psoriasis: A systematic review. Indian J. Dermatol. Venereol. Leprol. 2017, 83, 154–161. [Google Scholar] [CrossRef]
- Wang, J.; Zhang, S.; Xing, M.; Hong, S.; Liu, L.; Ding, X.-J.; Sun, X.-Y.; Luo, Y.; Wang, C.-X.; Zhang, M.; et al. Current evidence on the role of lipid lowering drugs in the treatment of psoriasis. Front. Med. 2022, 9, 900916. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- Cumpston, M.; Li, T.; Page, M.; Chandler, J.; Welch, V.; Higgins, J.P.; Thomas, J. Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst. Rev. 2019, 10, ED000142. [Google Scholar] [CrossRef]
- The EndNote Team. EndNote; Clarivate: Philadelphia, PA, USA, 2013. [Google Scholar]
- Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210. [Google Scholar] [CrossRef]
- Mattei, P.; Corey, K.; Kimball, A. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The correlation between disease severity and psychological burden in patients treated with biological therapies. Acad. Dermatol. Venereol. 2014, 28, 333–337. [Google Scholar] [CrossRef]
- Manchanda, Y.; De, A.; Das, S.; Chakraborty, D. Disease Assessment in Psoriasis. Indian J. Dermatol. 2023, 68, 278–281. [Google Scholar]
- Finlay, A.; Khan, G. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 1994, 19, 210–216. [Google Scholar] [CrossRef]
- Higgins, J.P.T.; Altman, D.G.; Gøtzsche, P.C.; Jüni, P.; Moher, D.; Oxman, A.D.; Savović, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.C.; et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011, 343, d5928. [Google Scholar] [CrossRef]
- The Cochrane Collaboration. Review Manager 5 (RevMan 5); The Cochrane Collaboration: Copenhagen, Denmark, 2020. [Google Scholar]
- Al Salman, M.; Ghiasi, M.; Farid, A.S.; Taraz, M.; Azizpour, A.; Mahmoudi, H. Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial. Dermatol. Ther. 2021, 34, e15075. [Google Scholar] [CrossRef]
- Chua, S.H.; Tioleco, G.S.; Dayrit, C.F.; Mojica, W.; Dofitas, B.; Frez, L. Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial. Indian J. Dermatol. Venereol. Leprol. 2017, 83, 441–447. [Google Scholar] [CrossRef]
- Faghihi, T.; Radfar, M.; Mehrabian, Z.; Ehsani, A.H.; Hemami, M.R. Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy 2011, 31, 1045–1050. [Google Scholar] [CrossRef]
- Jawed, F.; Rizvi, F.; Azhar, A.; Ara, J.; Naz, Z.; Iqbal, J. Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic Patients. Rawal Med. J. 2020, 45, 282–286. Available online: https://www.rmj.org.pk/?mno=83520 (accessed on 14 April 2024).
- Mohammadi, F.; Mohammadi, F.; Harofteh, F.Z.; Harofteh, F.Z.; Sahebnasagh, A.; Sahebnasagh, A.; Ghaneei, N.; Ghaneei, N.; Ardakani, M.E.Z.; Ardakani, M.E.Z.; et al. Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial. Ski. Res. Technol. 2024, 30, e13689. [Google Scholar] [CrossRef]
- Naseri, M.; Hadipour, A.; Sepaskhah, M.; Namazi, M.R. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: A double-blind, randomized, placebo-controlled study. Niger. J. Med. J. Natl. Assoc. Resid. Dr. Niger. 2010, 19, 58–61. [Google Scholar] [CrossRef]
- Ports, W.C.; Fayyad, R.; DeMicco, D.A.; Laskey, R.; Wolk, R. Effectiveness of Lipid-Lowering Statin Therapy in Patients with and without Psoriasis. Clin. Drug Investig. 2017, 37, 775–785. [Google Scholar] [CrossRef]
- Augustin, M.; Glaeske, G.; Radtke, M.; Christophers, E.; Reich, K.; Schäfer, I. Epidemiology and comorbidity of psoriasis in children. Br. J. Dermatol. 2010, 162, 633–636. [Google Scholar] [CrossRef]
- Caruso, R.; Botti, E.; Sarra, M.; Esposito, M.; Stolfi, C.; Diluvio, L.; Giustizieri, M.L.; Pacciani, V.; Mazzotta, A.; Campione, E.; et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat. Med. 2009, 15, 1013–1015. [Google Scholar] [CrossRef]
- Alwan, W.; Nestle, F.O. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin. Exp. Rheumatol. 2015, 33 (Suppl. S93), S2–S6. [Google Scholar]
- Van De Kerkhof, P.C.M. Therapeutic strategies: Rotational therapy and combinations. Clin. Exp. Dermatol. 2001, 26, 356–361. [Google Scholar] [CrossRef]
- Gonzalez-Cantero, A.; Boehncke, W.H.; De Sutter, J.; Zamorano, J.L.; Lambert, J.; Puig, L. Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Academy of Dermatology and Venerology. J. Eur. Acad. Dermatol. Venereol. 2023, 37, 1697–1705. [Google Scholar] [CrossRef]
- Trong, H.N.; Tat, T.N.; Anh, T.T.N.; Uyen, N.P.; Van, T.N.; Hau, K.T.; Gandolfi, M.; Satolli, F.; Feliciani, C.; Tirant, M.; et al. Efficacy of adding oral simvastatin to topical therapy for treatment of psoriasis: The vietnamese experience. Open Access Maced. J. Med. Sci. 2019, 7, 237–242. [Google Scholar] [CrossRef]
Study | Study Type | Location | Study Duration (Month) | Population | Interventions | Control | Sample Size | |
---|---|---|---|---|---|---|---|---|
Intervention | Control | |||||||
Al Salman et al. [35], 2021 | RCT | Iran | 3 | Patients with moderate to severe plaque-type psoriasis (PASI score under 20) undergoing NB-UVB phototherapy. | Simvastatin 40 mg/day + NB-UVB | Placebo + narrow-band UVB | 22 (2 lost) | 22 (2 lost) |
Faghihi et al. [37] 2011 | RCT | Iran | 3 | Patients aged 16 to 60 years diagnosed with acute or chronic plaque-type psoriasis, with body surface area (BSA) involvement exceeding 10%. | Atorvastatin 40 mg/day | Placebo | 20 | 20 |
Jawed et al. [38], 2020 | RCT | Pakistan | 6 | Patients of both genders aged 25 to 65 years with psoriasis, having a PASI score of less than 12 and hsCRP levels of 3 or higher | G1: atorvastatin 40 mg/day for 3 months then 20 mg/day for the next 3 months G2: atorvastatin 80 mg/day for 3 months then 40 mg/day for the next 3 months ** | Placebo ** | G1: 75 (9 lost) G2: 75 (5 lost) | 75 (5 lost) |
Naseri et al. [40], 2010 | RCT | Iran | 2 | Patients with plaque psoriasis | Simvastatin 40 mg/day ** | Placebo ** | 15 | 15 |
Mohammadi et al. [39], 2024 | RCT | Iran | 2 | Adult patients (18 years and older) with mild to moderate plaque psoriasis | G1: melatonin 0.5% cream twice/d G2: Topical Rosuvastatin 0.5% twice per day for 8 weeks | Placebo | G1: 27 (3 lost) G2: 25 (8 lost) | 25 (14 lost) |
Chua et al. [36], 2017 | RCT | Philippines | 6 | Patients between the ages of 19 and 65 diagnosed with mild to moderate chronic plaque psoriasis, having PASI scores below 10 | Atorvastatin 40 mg/day ** | Placebo ** | 14 (3 lost) | 14 (3 lost) |
Ports et al. [41], 2017 | post hoc analysis | United Kingdom | Patients with history of psoriasis or receiving its medications involved in three different trials | Atorvastatin 10 mg/day | Placebo | 21 | 31 |
Study | Study Arms | Sample Size | Age Mean ± SD | Sex, Males n (%) | Smoking (Yes) N (%) | PASI Mean (±SD) | DLQI Mean (±SD) |
---|---|---|---|---|---|---|---|
Al Salman et al. [35], 2021 | Simvastatin | 20 | 41 (±18.08) | 10 (50%) | NR | 9.34 (±3.75) | 10.2 (±8.13) |
Placebo | 20 | 46.9 (±17.4) | 12 (60%) | NR | 11.715 (±9.02) | 9.4 (±6.85) | |
Faghihi et al. [37] 2011 | Atorvastatin | 20 | 43.85 (±14.3) | 8 (40%) | NR | 7.42 (±1.9) | NR |
Placebo | 20 | 36.55 (±12.1) | 12 (60%) | NR | 6.92 (±1.76) | NR | |
Jawed et al. [38], 2020 | Atorvastatin 40 mg/day | 70 | 47.8 (±8.23) | 54 (77.15) | 44 (62.86%) | 10.89 (±1.19) | 19.6 (±1.98) |
Atorvastatin 80 mg/day | 67 | 47.9 (±8.42) | 52 (76.48) | 43 (63.24) | 10.99 (±0.711) | 19.77 (±1.43) | |
Placebo | 66 | 46.5 (±7.84) | 57 (86.37%) | 42 (63.64%) | 11.23 (±0.729) | 20.2 (±1.16) | |
Naseri et al. [40], 2010 | Simvastatin | 15 | 38.5 (±13.8) | 9 (60%) | NR | 9.51 | NR |
Placebo | 15 | 45.4 (±15.52) | 11 (73.3%) | NR | 5.64 | NR | |
Mohammadi et al. [39], 2024 | Rosuvastatin | 17 | 42.94 (±9.97) | 7 (41.2%) | 3 (17.6%) | 2.91 (±1.85) | 12.53 (±8.43) |
Placebo | 11 | 36.55 (±9.12) | 4 (36.4%) | 1 (9.1%) | 1.76 (±1.23) | 8.64 (±4.2) | |
Chua et al. [36], 2017 | Atorvastatin | 14 | 41.29 (±11.38) | 7 (50%) | NR | 5.49 (±2.78) | 11.5 (±6.04) |
Placebo | 14 | 40.71 (±12) | 4 (28.57%) | NR | 5.63 (±2.52) | 9.07 (±5.84) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aleid, A.M.; Almutairi, G.; Alrizqi, R.; Nukaly, H.Y.; Alkhanani, J.J.; AlHuraish, D.S.; Alshanti, H.Y.; Algaidi, Y.S.; Alyami, H.; Alrasheeday, A.; et al. The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis. Healthcare 2024, 12, 1526. https://doi.org/10.3390/healthcare12151526
Aleid AM, Almutairi G, Alrizqi R, Nukaly HY, Alkhanani JJ, AlHuraish DS, Alshanti HY, Algaidi YS, Alyami H, Alrasheeday A, et al. The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis. Healthcare. 2024; 12(15):1526. https://doi.org/10.3390/healthcare12151526
Chicago/Turabian StyleAleid, Abdulsalam Mohammed, Ghadah Almutairi, Rudhab Alrizqi, Houriah Yasir Nukaly, Jomanah Jamal Alkhanani, Deemah Salem AlHuraish, Hawazin Yasser Alshanti, Yaser Sami Algaidi, Hanan Alyami, Awatif Alrasheeday, and et al. 2024. "The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis" Healthcare 12, no. 15: 1526. https://doi.org/10.3390/healthcare12151526